UK Study: How Smart Insulin Pumps Are Changing Diabetes Care

A study from the UK, conducted by researchers at the prestigious Department of Diabetes at King's College London, examines the growing role of Automated Insulin Delivery (AID) systems — a breakthrough technology that connects continuous glucose monitors (CGMs) with smart insulin pumps to automatically manage blood sugar levels in people with diabetes.

What Are Automated Insulin Delivery Systems?

AID systems — sometimes called "closed-loop" or "artificial pancreas" systems — work by linking two key devices: a continuous glucose monitor (CGM), which tracks blood sugar levels in real time, and an insulin pump (also known as a continuous subcutaneous insulin infusion device, or CSII). A built-in algorithm analyzes your glucose readings and automatically adjusts insulin delivery — reducing the constant manual decision-making that burdens people with insulin-treated diabetes every single day.

Think of it as cruise control for your blood sugar.

What the UK Researchers Found

The King's College London team reviewed both clinical trial data and real-world outcomes for AID systems, with a primary focus on Type 1 diabetes (T1D), while also examining benefits for people with Type 2 diabetes (T2D) and other diabetes subtypes. Key findings include:

• Improved blood sugar control: AID users consistently spent more time in the target glucose range of 70–180 mg/dL (the equivalent of 3.9–10.0 mmol/L used in UK research), reducing dangerous highs and lows.
• Better quality of life: Patients reported reduced mental burden and improved sleep — major wins for long-term diabetes management.
• Expanded benefits beyond Type 1: Emerging evidence suggests AID systems may also help people with Type 2 diabetes who require insulin, broadening the potential impact significantly.
• Real-world results match clinical trials: Crucially, the benefits seen in controlled studies appear to hold up in everyday life — a finding that strengthens the case for wider adoption.

Converting the Numbers for US Patients

UK and US researchers both target a time-in-range of 70–180 mg/dL for most adults with diabetes — good news for US patients reading international research, as the core glucose targets align closely. The American Diabetes Association (ADA) recommends that people with T1D spend more than 70% of their time in this range. AID systems in reviewed studies regularly helped patients meet or exceed this goal.

Why This Matters for US Patients

AID systems are already available in the United States — including FDA-approved options like the Omnipod 5 and Medtronic MiniMed 780G — but adoption remains uneven due to cost, insurance coverage gaps, and limited provider familiarity. This comprehensive UK review reinforces that these systems deliver real, meaningful improvements in blood sugar control and daily quality of life, not just in research labs but in real-world use.

For US patients currently using multiple daily injections (MDI) or a standard pump without CGM connectivity, this research is a strong signal to ask your endocrinologist: "Am I a candidate for an AID system?" The evidence — now supported by international consensus — says the answer may well be yes.

The researchers also acknowledge current limitations, including device compatibility issues and access barriers, and call for continued innovation — challenges that resonate equally on both sides of the Atlantic.

Citation

Anandhakrishnan A, Hussain S. Automating insulin delivery through pump and continuous glucose monitoring connectivity: Maximizing opportunities to improve outcomes. Diabetes, Obesity & Metabolism. 2024. DOI: 10.1111/dom.15920. PMID: 39291355.